Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
- : Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
- : Resverlogix Announces $15.1 Million of Private Placements
- : Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases